Endocrinol Metab.  2024 Jun;39(3):461-467. 10.3803/EnM.2023.1863.

Clinical Manifestations of Malignant Struma Ovarii: A Retrospective Case Series in a Tertiary Hospital in Korea

• Ryu HJ
• Leem DE
• Yoo JH
• Kim TH
• Kim SW
• Chung JH

• KMID: 2556638
• DOI: http://doi.org/10.3803/EnM.2023.1863

Abstract

Background
Malignant struma ovarii (MSO) is a very rare disease in which thyroid cancer originates from the ovary. Because it is rare for endocrinologists to encounter patients with MSO, endocrinologists may have a limited understanding of the disease. Therefore, we analyzed and introduced its incidence and clinical course in a tertiary hospital in Korea.
Methods
We retrospectively investigated the clinical data of 170 patients who underwent surgery for struma ovarii at the Department of Obstetrics and Gynecology of Samsung Medical Center from 1994 to May 2023.
Results
Among 170 patients with struma ovarii, 15 (8.8%) were diagnosed with MSO. The median age of patients with MSO was 48 years (range, 30 to 74), and the median tumor size was 3.3 cm (range, 0.5 to 11.0). Papillary thyroid carcinoma (46.7%) was the most common subtypes followed by follicular thyroid carcinoma (26.7%). All patients were diagnosed after surgery, with no predictions from preoperative imaging. The surgical extent of gynecological surgery was variable. Four patients (26.7%) underwent thyroidectomy for thyroid cancer, while one underwent total thyroidectomy and radioactive iodine therapy for MSO with peritoneal metastasis. Except for one patient who underwent hemithyroidectomy, thyroid stimulating hormone suppression therapy was performed in four patients. Only 53% of MSO patients were consulted by an endocrinologist. With a median follow-up period of 33 months (range, 4 to 156), 11 patients remained disease-free, one experienced progression with peritoneal seeding, and the remaining one was in treatment. There have been no recurrences or deaths due to MSO.
Conclusion
An endocrinologist should be involved in establishing a therapeutic plan for MSO, for which the overall prognosis is generally favorable.

Keyword

Struma ovarii; Malignant struma ovarii; Ovarian neoplasms; Thyroid neoplasms

Figure

• 

  Fig. 1. Numbers of cases of malignant struma ovarii (MSO) and benign struma ovarii managed by Samsung Medical Center by 3-year periods from 1995 to 2021.

Reference

1. Egan C, Stefanova D, Thiesmeyer JW, Lee YJ, Greenberg J, Beninato T, et al. Proposed risk stratification and patterns of radioactive iodine therapy in malignant struma ovarii. Thyroid. 2022; 32:1101–8.

2. Hemli JM, Barakate MS, Appleberg M, Delbridge LW. Papillary carcinoma of the thyroid arising in struma ovari: report of a case and review of management guidelines. Gynecol Endocrinol. 2001; 15:243–7.

3. Rosenblum NG, LiVolsi VA, Edmonds PR, Mikuta JJ. Malignant struma ovarii. Gynecol Oncol. 1989; 32:224–7.

4. Yoo SC, Chang KH, Lyu MO, Chang SJ, Ryu HS, Kim HS. Clinical characteristics of struma ovarii. J Gynecol Oncol. 2008; 19:135–8.

5. Devaney K, Snyder R, Norris HJ, Tavassoli FA. Proliferative and histologically malignant struma ovarii: a clinicopathologic study of 54 cases. Int J Gynecol Pathol. 1993; 12:333–43.

6. Makani S, Kim W, Gaba AR. Struma ovarii with a focus of papillary thyroid cancer: a case report and review of the literature. Gynecol Oncol. 2004; 94:835–9.

7. Zalel Y, Seidman DS, Oren M, Achiron R, Gotlieb W, Mashiach S, et al. Sonographic and clinical characteristics of struma ovarii. J Ultrasound Med. 2000; 19:857–61.

8. Goffredo P, Sawka AM, Pura J, Adam MA, Roman SA, Sosa JA. Malignant struma ovarii: a population-level analysis of a large series of 68 patients. Thyroid. 2015; 25:211–5.

9. Robboy SJ, Shaco-Levy R, Peng RY, Snyder MJ, Donahue J, Bentley RC, et al. Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread. Int J Gynecol Pathol. 2009; 28:405–22.

10. Shaco-Levy R, Bean SM, Bentley RC, Robboy SJ. Natural history of biologically malignant struma ovarii: analysis of 27 cases with extraovarian spread. Int J Gynecol Pathol. 2010; 29:212–27.

11. Brusca N, Del Duca SC, Salvatori R, D’Agostini A, Cannas P, Santaguida MG, et al. A case report of thyroid carcinoma confined to ovary and concurrently occult in the thyroid: is conservative treatment always advised? Int J Endocrinol Metab. 2015; 13:e18220.

12. Cui Y, Yao J, Wang S, Zhao J, Dong J, Liao L. The clinical and pathological characteristics of malignant struma ovarii: an analysis of 144 published patients. Front Oncol. 2021; 11:645156.

13. Addley S, Mihai R, Alazzam M, Dhar S, Soleymani Majd H. Malignant struma ovarii: surgical, histopathological and survival outcomes for thyroid-type carcinoma of struma ovarii with recommendations for standardising multi-modal management: a retrospective case series sharing the experience of a single institution over 10 years. Arch Gynecol Obstet. 2021; 303:863–70.

14. Marti JL, Clark VE, Harper H, Chhieng DC, Sosa JA, Roman SA. Optimal surgical management of well-differentiated thyroid cancer arising in struma ovarii: a series of 4 patients and a review of 53 reported cases. Thyroid. 2012; 22:400–6.

15. Anagnostou E, Polymeris A, Morphopoulos G, Travlos A, Sarantopoulou V, Papaspyrou I. An unusual case of malignant struma ovarii causing thyrotoxicosis. Eur Thyroid J. 2016; 5:207–11.

16. Jean S, Tanyi JL, Montone K, McGrath C, Lage-Alvarez MM, Chu CS. Papillary thyroid cancer arising in struma ovarii. J Obstet Gynaecol. 2012; 32:222–6.

17. Wolff EF, Hughes M, Merino MJ, Reynolds JC, Davis JL, Cochran CS, et al. Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer. Thyroid. 2010; 20:981–7.

18. Neyrand S, Trecourt A, Lopez J, Just PA, Descotes F, Borson-Chazot F, et al. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii. Histopathology. 2024; 84:291–300.